非小细胞肺癌治疗的最新进展
Recent advances in the management of non-small cell lung cancer.
作者信息
Shojaee Samira, Nana-Sinkam Patrick
机构信息
Division of Pulmonary and Critical Care Medicine, Virginia Commonwealth University, Richmond, USA.
出版信息
F1000Res. 2017 Dec 7;6:2110. doi: 10.12688/f1000research.11471.1. eCollection 2017.
Abstract
Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.
摘要
肺癌是男性和女性癌症相关死亡的首要原因。然而，在过去几年中，我们见证了治疗效果的改善，这在很大程度上归因于早期检测、加大烟草控制力度、改进手术方法以及新型靶向治疗的发展。目前，临床实践中有几种新型疗法，包括针对可操作突变的疗法以及最近的免疫治疗药物。免疫疗法是根除这种致命疾病方面取得的最重大进展。鉴于肺癌治疗格局不断变化，在此我们概述非小细胞肺癌治疗的最新进展。
相似文献
1
Recent advances in the management of non-small cell lung cancer.非小细胞肺癌治疗的最新进展
F1000Res. 2017 Dec 7;6:2110. doi: 10.12688/f1000research.11471.1. eCollection 2017.
2
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
3
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
4
Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.靶向治疗与免疫治疗的进展——未来十年非小细胞肺癌的治疗将如何改变：一项叙述性综述
Ann Transl Med. 2023 Aug 30;11(10):358. doi: 10.21037/atm-22-4444. Epub 2023 Mar 23.
5
Management and future directions in non-small cell lung cancer with known activating mutations.已知具有激活突变的非小细胞肺癌的管理及未来方向
Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353.
6
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.靶向治疗应用于非小细胞肺癌的更早期阶段：新出现的证据、争议及未来挑战
Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2.
7
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.在常规检测中无 EGFR 和 ALK 改变的晚期非小细胞肺癌患者中，靶向 DNA 测序的获益。
Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21.
8
Developments in systemic therapies for the management of lung cancer.肺癌治疗中全身治疗的进展
Intern Med J. 2021 Dec;51(12):2012-2020. doi: 10.1111/imj.15609.
9
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer.新型靶点与新型疗法：非小细胞肺癌不断变化的格局
Cancers (Basel). 2023 May 21;15(10):2855. doi: 10.3390/cancers15102855.
10
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.非小细胞肺癌脑转移的治疗。
Int J Mol Sci. 2021 Jan 8;22(2):593. doi: 10.3390/ijms22020593.
引用本文的文献
1
Lung cancer: Animal model of lung cancer, molecular carcinogenesis of lung cancer, and antitumor effect of against lung cancer.肺癌：肺癌动物模型、肺癌的分子致癌作用以及（某种物质）对肺癌的抗肿瘤作用。 （这里原文“against lung cancer”前缺少关键信息，推测可能是某种物质或治疗手段等，翻译只能按现有内容尽量准确呈现）
Open Vet J. 2025 Feb;15(2):482-503. doi: 10.5455/OVJ.2025.v15.i2.1. Epub 2025 Feb 28.
2
Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials.各种中药注射剂联合西药治疗非小细胞肺癌的疗效比较：一项随机对照试验的贝叶斯网络荟萃分析
Front Pharmacol. 2022 Nov 10;13:1037620. doi: 10.3389/fphar.2022.1037620. eCollection 2022.
3
Application Value of Serum Multi-Antibody Combined Detection in Differential Diagnosis and Typing of Lung Cancer.血清多抗体联合检测在肺癌鉴别诊断及分型中的应用价值
J Oncol. 2022 Jan 28;2022:8944263. doi: 10.1155/2022/8944263. eCollection 2022.
4
Lamprey Immune Protein Mediates Apoptosis of Lung Cancer Cells Via the Endoplasmic Reticulum Stress Signaling Pathway.七鳃鳗免疫蛋白通过内质网应激信号通路介导肺癌细胞凋亡。
Front Oncol. 2021 Jul 7;11:663600. doi: 10.3389/fonc.2021.663600. eCollection 2021.
5
Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.内皮生长因子受体突变型肺癌与术后护理管理：一刀切并不适用。
Ann Transl Med. 2020 Dec;8(24):1697. doi: 10.21037/atm-20-4408.
6
Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.顺势疗法作为附加治疗可能改善非小细胞肺癌患者的生活质量并延长其生存时间：一项前瞻性、随机、安慰剂对照、双盲、三臂、多中心研究。
Oncologist. 2020 Dec;25(12):e1930-e1955. doi: 10.1002/onco.13548. Epub 2020 Nov 7.
7
CtBP1 promotes tumour-associated macrophage infiltration and progression in non-small-cell lung cancer.CtBP1 促进非小细胞肺癌中肿瘤相关巨噬细胞的浸润和进展。
J Cell Mol Med. 2020 Oct;24(19):11445-11456. doi: 10.1111/jcmm.15751. Epub 2020 Sep 10.
8
Accomplishing an adaptive clinical trial for cancer: Valuation practices and care work across the laboratory and the clinic.完成癌症适应性临床试验：实验室和临床之间的评估实践和护理工作。
Soc Sci Med. 2020 May;252:112949. doi: 10.1016/j.socscimed.2020.112949. Epub 2020 Mar 24.
9
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.在新建立的肺癌脑转移的临床前模型中出现了耐药性。
BMC Cancer. 2020 Apr 7;20(1):292. doi: 10.1186/s12885-020-06808-2.
10
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.克唑替尼诱导非小细胞肺癌的免疫原性细胞死亡。
Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3.
本文引用的文献
1
Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.MET 外显子 14 跳跃突变阳性非小细胞肺癌对克唑替尼和卡博替尼治疗有反应的病例系列研究。
Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.
2
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.达拉非尼联合曲美替尼与达拉非尼单药治疗转移性BRAF V600E/K突变黑色素瘤患者：一项3期研究的长期生存和安全性分析
Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
3
Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.肺癌——美国癌症联合委员会第八版癌症分期手册的重大变化。
CA Cancer J Clin. 2017 Mar;67(2):138-155. doi: 10.3322/caac.21390. Epub 2017 Jan 31.
4
Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.欧洲胸外科医师协会（ESTS）关于欧洲肺癌计算机断层扫描筛查的建议。
Eur J Cardiothorac Surg. 2017 Mar 1;51(3):411-420. doi: 10.1093/ejcts/ezw418.
5
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
6
Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.化疗联合放射治疗能否提高非寡转移IV期非小细胞肺癌患者的总生存率？两项前瞻性研究的二次分析
BMC Cancer. 2016 Nov 21;16(1):908. doi: 10.1186/s12885-016-2952-3.
7
Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients.同步M1b-c期IV期非小细胞肺癌患者的肺切除术
Ann Thorac Surg. 2017 May;103(5):1594-1599. doi: 10.1016/j.athoracsur.2016.08.098. Epub 2016 Nov 15.
8
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.奥希替尼治疗预处理 EGFR Thr790Met 阳性的晚期非小细胞肺癌（AURA2）：一项多中心、开放标签、单臂、2 期研究。
Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.
9
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.高水平 MET 扩增的非小细胞肺癌即使 MET 外显子 14 无改变，对克唑替尼也有应答。
J Thorac Oncol. 2017 Jan;12(1):141-144. doi: 10.1016/j.jtho.2016.09.116. Epub 2016 Sep 21.
10
Routine molecular profiling of patients with NSCLC - Authors' reply.非小细胞肺癌患者的常规分子谱分析——作者回复
Lancet. 2016 Sep 10;388(10049):1054-1055. doi: 10.1016/S0140-6736(16)31136-9.
Zotero 插件